Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells

Chikara Muraki, Noritaka Ohga, Yasuhiro Hida, Hiroshi Nishihara, Yasutaka Kato, Kunihiko Tsuchiya, Kohei Matsuda, Yasunori Totsuka, Masanobu Shindoh, Kyoko Hida

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Tumor angiogenesis is necessary for solid tumor progression and metastasis. Cyclooxygenase (COX)-2 is known to play an important role in cancer growth and invasion, and it activates the signaling pathways controlling cell proliferation, migration, apoptosis, and angiogenesis. COX-2 is reported to be expressed in many cancer cells. Several studies have reported successful treatment of cancer cells with COX-2 inhibitors (COX-2is). However, the effect of COX-2 inhibition on the tumor endothelium remains to be elucidated. Our study shows that COX-2 is expressed in the vasculature of surgically resected human tumors. To investigate the effects of COX-2 inhibition on the tumor endothelium in vitro, we isolated tumor endothelial cells (TECs) from human melanoma and oral carcinoma xenografts in mice, in which we confirmed that tumor growth was suppressed by inhibiting angiogenesis with the COX-2is NS398. COX-2 mRNA was upregulated in TECs compared to normal endothelial cells (NECs). Cell migration and proliferation were suppressed by NS398 in TECs but not in NECs. The effects of NS398 in vivo were consistent with the in vitro results. The number of CD133 +/vascular endothelial growth factor receptor-2 + cells in circulation was significantly suppressed by COX-2 inhibition. In addition, the number of progenitor marker-positive cells decreased in the tumor blood vessels after COX-2i treatment, which suggests that the homing of progenitor cells into the tumor was also blocked. We conclude that NS398 specifically targets both TECs and vascular progenitor cells without affecting NECs.

Original languageEnglish
Pages (from-to)59-70
Number of pages12
JournalInternational Journal of Cancer
Volume130
Issue number1
DOIs
Publication statusPublished - 2012 Jan 11
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Blood Vessels
Neoplasms
Endothelial Cells
Prostaglandin-Endoperoxide Synthases
Endothelial Progenitor Cells
Endothelium
Cell Movement
Stem Cells
Cell Proliferation
Vascular Tissue Neoplasms
Vascular Endothelial Growth Factor Receptor-2
Cyclooxygenase 2 Inhibitors
Growth
Heterografts
Melanoma

Keywords

  • angiogenesis
  • COX-2
  • EPCs
  • TECs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells. / Muraki, Chikara; Ohga, Noritaka; Hida, Yasuhiro; Nishihara, Hiroshi; Kato, Yasutaka; Tsuchiya, Kunihiko; Matsuda, Kohei; Totsuka, Yasunori; Shindoh, Masanobu; Hida, Kyoko.

In: International Journal of Cancer, Vol. 130, No. 1, 11.01.2012, p. 59-70.

Research output: Contribution to journalArticle

Muraki, C, Ohga, N, Hida, Y, Nishihara, H, Kato, Y, Tsuchiya, K, Matsuda, K, Totsuka, Y, Shindoh, M & Hida, K 2012, 'Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells', International Journal of Cancer, vol. 130, no. 1, pp. 59-70. https://doi.org/10.1002/ijc.25976
Muraki, Chikara ; Ohga, Noritaka ; Hida, Yasuhiro ; Nishihara, Hiroshi ; Kato, Yasutaka ; Tsuchiya, Kunihiko ; Matsuda, Kohei ; Totsuka, Yasunori ; Shindoh, Masanobu ; Hida, Kyoko. / Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells. In: International Journal of Cancer. 2012 ; Vol. 130, No. 1. pp. 59-70.
@article{f4ede008bcfc400e9b0345e3c76b172a,
title = "Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells",
abstract = "Tumor angiogenesis is necessary for solid tumor progression and metastasis. Cyclooxygenase (COX)-2 is known to play an important role in cancer growth and invasion, and it activates the signaling pathways controlling cell proliferation, migration, apoptosis, and angiogenesis. COX-2 is reported to be expressed in many cancer cells. Several studies have reported successful treatment of cancer cells with COX-2 inhibitors (COX-2is). However, the effect of COX-2 inhibition on the tumor endothelium remains to be elucidated. Our study shows that COX-2 is expressed in the vasculature of surgically resected human tumors. To investigate the effects of COX-2 inhibition on the tumor endothelium in vitro, we isolated tumor endothelial cells (TECs) from human melanoma and oral carcinoma xenografts in mice, in which we confirmed that tumor growth was suppressed by inhibiting angiogenesis with the COX-2is NS398. COX-2 mRNA was upregulated in TECs compared to normal endothelial cells (NECs). Cell migration and proliferation were suppressed by NS398 in TECs but not in NECs. The effects of NS398 in vivo were consistent with the in vitro results. The number of CD133 +/vascular endothelial growth factor receptor-2 + cells in circulation was significantly suppressed by COX-2 inhibition. In addition, the number of progenitor marker-positive cells decreased in the tumor blood vessels after COX-2i treatment, which suggests that the homing of progenitor cells into the tumor was also blocked. We conclude that NS398 specifically targets both TECs and vascular progenitor cells without affecting NECs.",
keywords = "angiogenesis, COX-2, EPCs, TECs",
author = "Chikara Muraki and Noritaka Ohga and Yasuhiro Hida and Hiroshi Nishihara and Yasutaka Kato and Kunihiko Tsuchiya and Kohei Matsuda and Yasunori Totsuka and Masanobu Shindoh and Kyoko Hida",
year = "2012",
month = "1",
day = "11",
doi = "10.1002/ijc.25976",
language = "English",
volume = "130",
pages = "59--70",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells

AU - Muraki, Chikara

AU - Ohga, Noritaka

AU - Hida, Yasuhiro

AU - Nishihara, Hiroshi

AU - Kato, Yasutaka

AU - Tsuchiya, Kunihiko

AU - Matsuda, Kohei

AU - Totsuka, Yasunori

AU - Shindoh, Masanobu

AU - Hida, Kyoko

PY - 2012/1/11

Y1 - 2012/1/11

N2 - Tumor angiogenesis is necessary for solid tumor progression and metastasis. Cyclooxygenase (COX)-2 is known to play an important role in cancer growth and invasion, and it activates the signaling pathways controlling cell proliferation, migration, apoptosis, and angiogenesis. COX-2 is reported to be expressed in many cancer cells. Several studies have reported successful treatment of cancer cells with COX-2 inhibitors (COX-2is). However, the effect of COX-2 inhibition on the tumor endothelium remains to be elucidated. Our study shows that COX-2 is expressed in the vasculature of surgically resected human tumors. To investigate the effects of COX-2 inhibition on the tumor endothelium in vitro, we isolated tumor endothelial cells (TECs) from human melanoma and oral carcinoma xenografts in mice, in which we confirmed that tumor growth was suppressed by inhibiting angiogenesis with the COX-2is NS398. COX-2 mRNA was upregulated in TECs compared to normal endothelial cells (NECs). Cell migration and proliferation were suppressed by NS398 in TECs but not in NECs. The effects of NS398 in vivo were consistent with the in vitro results. The number of CD133 +/vascular endothelial growth factor receptor-2 + cells in circulation was significantly suppressed by COX-2 inhibition. In addition, the number of progenitor marker-positive cells decreased in the tumor blood vessels after COX-2i treatment, which suggests that the homing of progenitor cells into the tumor was also blocked. We conclude that NS398 specifically targets both TECs and vascular progenitor cells without affecting NECs.

AB - Tumor angiogenesis is necessary for solid tumor progression and metastasis. Cyclooxygenase (COX)-2 is known to play an important role in cancer growth and invasion, and it activates the signaling pathways controlling cell proliferation, migration, apoptosis, and angiogenesis. COX-2 is reported to be expressed in many cancer cells. Several studies have reported successful treatment of cancer cells with COX-2 inhibitors (COX-2is). However, the effect of COX-2 inhibition on the tumor endothelium remains to be elucidated. Our study shows that COX-2 is expressed in the vasculature of surgically resected human tumors. To investigate the effects of COX-2 inhibition on the tumor endothelium in vitro, we isolated tumor endothelial cells (TECs) from human melanoma and oral carcinoma xenografts in mice, in which we confirmed that tumor growth was suppressed by inhibiting angiogenesis with the COX-2is NS398. COX-2 mRNA was upregulated in TECs compared to normal endothelial cells (NECs). Cell migration and proliferation were suppressed by NS398 in TECs but not in NECs. The effects of NS398 in vivo were consistent with the in vitro results. The number of CD133 +/vascular endothelial growth factor receptor-2 + cells in circulation was significantly suppressed by COX-2 inhibition. In addition, the number of progenitor marker-positive cells decreased in the tumor blood vessels after COX-2i treatment, which suggests that the homing of progenitor cells into the tumor was also blocked. We conclude that NS398 specifically targets both TECs and vascular progenitor cells without affecting NECs.

KW - angiogenesis

KW - COX-2

KW - EPCs

KW - TECs

UR - http://www.scopus.com/inward/record.url?scp=79958154873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958154873&partnerID=8YFLogxK

U2 - 10.1002/ijc.25976

DO - 10.1002/ijc.25976

M3 - Article

VL - 130

SP - 59

EP - 70

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -